Key Highlights
- agilon health (NYSE:AGL) dropped about 21% on November 18, 2026 and traded near USD 115, a share price that reflects a 1-for-25 Reverse Stock Split earlier this year.
- No company announcement was identified. The slide tracked Humana's 12.98% fall and UnitedHealth's 10.21% fall after a proposed Medicare Advantage audit rule.
- Adjusted EPS for the third quarter was USD 1.97, well above an expected loss, with Revenue of USD 1.51 billion and 2026 adjusted EBITDA guidance lifted to USD 145 million to USD 155 million.
- On November 18 an analyst kept a hold rating and a USD 112 target, close to the price at which the stock was changing hands.
Caught Up in the Managed Care Selloff
agilon health (NYSE:AGL) works alongside primary care doctors who manage Medicare Advantage patients under value-based contracts, with gains and losses on medical spending split between the parties. This model ties the company closely to Medicare Advantage economics, which faced severe strain this week. The Department of Health and Human Services, on November 16, advanced a rule to project audit error rates from sampled patient records onto complete Medicare Advantage contracts, beginning with 2018 payments, and the government estimates recoveries of about USD 90.2 billion over 2027 to 2036. Insurers fell again on November 18: Humana dropped 12.98%, UnitedHealth 10.21%, Elevance 7.63% and Centene 7.03%, while the health care sector lost 2.20%. Since no company development explains agilon's roughly 21% fall, the tie to the proposal rests on timing and exposure, not a stated reason. Smaller insurer payouts could eventually trim resources for provider partners like agilon, which helps account for the parallel decline.
Solid Results Overshadowed
Shares fell even though the latest figures were encouraging. Third-quarter adjusted Earnings Per Share were USD 1.97, versus an anticipated loss of USD 1.22, while revenue of USD 1.51 billion surpassed the USD 1.46 billion consensus. The 2026 adjusted EBITDA forecast was raised to a range of USD 145 million to USD 155 million from a previous midpoint of around USD 85 million. Management credits stricter oversight of clinical programs and lower medical costs per member. The lofty share price reflects a 1-for-25 reverse split that became effective March 30, 2026, undertaken to keep the price above USD 1.00 and retain the New York Stock Exchange listing.
What Lies Ahead
The proposed rule is set for Federal Register publication on November 19, with comments accepted through January 19, 2027. Insurers and provider organizations are likely to object, and a federal court in Texas has previously voided similar provisions from a 2023 regulation on procedural grounds, so the outcome is uncertain. For agilon, the main questions are how insurers would divide any recovered sums under their contracts and whether provider payment rates tighten. Fourth-quarter results and 2027 guidance will show whether cost progress holds. Until the regulatory path is clearer, the stock may keep moving with Medicare Advantage insurers more than with the company's operating performance.
Where Things Stand
agilon health (NYSE:AGL) dropped roughly 21% as Medicare Advantage stocks came under pressure over a proposed CMS audit rule, despite better third-quarter figures and raised guidance. Comments due January 19, 2027 will influence the next phase.






Please wait processing your request...